Algernon Pharmaceuticals (CSE: AGN) has entered into a clinical trial agreement with Yale University to investigate the use of DMT for the treatment of depression. The trial’s principal investigator is Professor Deepak Cyril D’Souza, an experienced researcher with DMT and other controlled substances.
“After careful consideration, we chose to support Dr D’Souza’s clinical DMT study and work with Yale University,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “Although the treatment of psychiatric disorders with DMT are not the Company’s current focus, we have patents pending on novel forms of DMT which could potentially be used across a broad range of diseases. In addition, we believe the data generated from this study may help inform Algernon’s stroke research program.”
Moreau continued, “A rising tide lifts all boats, and we feel a corporate responsibility as well to improve global awareness and support psychedelic medicine research when possible. It is in that spirit that we also chose to become the lead sponsor of Wonderland, the world’s largest conference on psychedelic medicine to be held November 3-5 in Miami.”
It’s always nice to see a company make moves that show a glimmer of altruism and desire to progress the betterment of humanity.
AGN.c is currently trading at $2.86, valued at $6.47 million.
https://ceo.ca/@globenewswire/algernon-pharmaceuticals-enters-into-a-clinical-trial